MXPA04004321A - Anticuerpo monoclonal contra virus de hepatitis e o su fragmento con actividad de enlace y uso del mismo. - Google Patents

Anticuerpo monoclonal contra virus de hepatitis e o su fragmento con actividad de enlace y uso del mismo.

Info

Publication number
MXPA04004321A
MXPA04004321A MXPA04004321A MXPA04004321A MXPA04004321A MX PA04004321 A MXPA04004321 A MX PA04004321A MX PA04004321 A MXPA04004321 A MX PA04004321A MX PA04004321 A MXPA04004321 A MX PA04004321A MX PA04004321 A MXPA04004321 A MX PA04004321A
Authority
MX
Mexico
Prior art keywords
present
monoclonal antibodies
hepatitis
polypeptides
recombination
Prior art date
Application number
MXPA04004321A
Other languages
English (en)
Inventor
He Zhiquiang
Original Assignee
Yang Sheng Tang Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4672637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA04004321(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yang Sheng Tang Co Ltd filed Critical Yang Sheng Tang Co Ltd
Publication of MXPA04004321A publication Critical patent/MXPA04004321A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/28011—Hepeviridae
    • C12N2770/28111—Hepevirus, e.g. hepatitis E virus
    • C12N2770/28122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/28011—Hepeviridae
    • C12N2770/28111—Hepevirus, e.g. hepatitis E virus
    • C12N2770/28134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)

Abstract

La presente invencion se refiere a un anticuerpo monoclonal que se enlaza especificamente a polipeptido(s) que comprenden la secuencia de aminoacidos como se establece en SEQ ID No. 1, del virus de la hepatitis E ORF 2 o sus variantes conservadas o sus fragmentos activos, u otros anticuerpos monoclonales contra ORF2, que pueden tener una reaccion cruzada con el anticuerpo monoclonal de la presente invencion, y su secuencia de nucleotidos o su secuencia degenerada; a la determinante antigenica en el virus de la hepatitis E ORF2; a un metodo para separar por exclusion un polipeptido aislado o recombinado o un analogo de polipeptido, que tiene la misma propiedad de enlazarse especificamente al anticuerpo monoclonal 8C11 y/o 8H3 como la determinante antigenica 1) o 3) del virus de la hepatitis E ORF2; a un polipeptido o analogo de polipeptido separado por exclusion por el metodo anterior, y su secuencia de nucleotidos o secuencia degenerada; a un uso del polipeptido o analogo del polipeptido en la preparacion de un medicamento para el diagnostico y/o prevencion de infeccion por virus de la hepatitis E; a un kit de diagnostico para infeccion por virus de la hepatitis E y a una composicion de vacuna para la profilaxis de infeccion por virus de la hepatitis E; al uso de los anticuerpos monoclonales o sus fragmentos activos o variantes conservadas, en la preparacion de un medicamento para el diagnostico, profilaxis y/o tratamiento de infeccion por virus de la hepatitis E; a una composicion farmaceutica para la profilaxis y/o tratamiento de infeccion por virus de la hepatitis e y un metodo para la profilaxis y/o tratamiento de infeccion por virus de la hepatitis E; a un vector de expresion recombinante que comprende la molecula de nucleotido en la presente invencion y una celula hospedadora transformada con el vector de expresion recombinante que puede expresar el anticuerpo monoclonal y sus variantes conservadas o fragmentos activos o polipeptidos o analogos de polipeptidos.
MXPA04004321A 2001-11-08 2002-11-08 Anticuerpo monoclonal contra virus de hepatitis e o su fragmento con actividad de enlace y uso del mismo. MXPA04004321A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN01134643 2001-11-08
PCT/CN2002/000797 WO2003040187A1 (fr) 2001-11-08 2002-11-08 Anticorps monoclonaux du virus de l'hepatite e ou fragments liants en provenant et utilisation correspondante

Publications (1)

Publication Number Publication Date
MXPA04004321A true MXPA04004321A (es) 2004-08-11

Family

ID=4672637

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04004321A MXPA04004321A (es) 2001-11-08 2002-11-08 Anticuerpo monoclonal contra virus de hepatitis e o su fragmento con actividad de enlace y uso del mismo.

Country Status (9)

Country Link
US (2) US7786264B2 (es)
EP (2) EP2322625B8 (es)
JP (3) JP2005524386A (es)
KR (1) KR101020256B1 (es)
CN (1) CN100339395C (es)
AU (1) AU2002349727B2 (es)
BR (2) BR122015016384B8 (es)
MX (1) MXPA04004321A (es)
WO (1) WO2003040187A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003040187A1 (fr) * 2001-11-08 2003-05-15 Yang Sheng Tang Company Limited Anticorps monoclonaux du virus de l'hepatite e ou fragments liants en provenant et utilisation correspondante
CN1850855B (zh) * 2006-05-26 2012-08-29 厦门大学 用于免疫或制备单克隆抗体的方法和组合物
CN101595389B (zh) * 2006-12-14 2012-10-10 浙江我武生物科技股份有限公司 用于变应原活性测定的标准血清混合物的制备方法及其用途
AR070141A1 (es) * 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
JP5297734B2 (ja) * 2008-09-17 2013-09-25 株式会社Ｎｂｃメッシュテック スギ花粉アレルゲンへの結合能を有するペプチド
US8362203B2 (en) * 2009-02-10 2013-01-29 Wayne State University Non-natural peptides as models for the development of antibiotics
BR112012023010A8 (pt) 2010-03-12 2017-12-26 Immunogen Inc Anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37
EA201391342A1 (ru) * 2011-04-01 2014-11-28 Иммьюноджен, Инк. Cd37-связывающие молекулы и их иммуноконъюгаты
JP6048845B2 (ja) 2011-06-01 2016-12-21 シャモン ユニヴァーシティー ジフテリア毒素の無毒性突然変異体ｃｒｍ１９７又はその断片を含む融合タンパク質
EP2956468B1 (en) 2013-02-12 2020-06-10 Bristol-Myers Squibb Company Tangential flow filtration based protein refolding methods
CN105445463A (zh) * 2014-09-25 2016-03-30 苏州新波生物技术有限公司 一种戊肝IgG抗体检测试剂盒及其制备方法和应用
US20170000900A1 (en) 2015-06-08 2017-01-05 Immunogen, Inc. Anti-cd37 immunoconjugate and anti-cd20 antibody combinations
EP3341414A4 (en) 2015-08-28 2019-03-27 Debiopharm International SA ANTIBODIES AND ASSAYS FOR DETECTION OF CD37
WO2018083633A1 (en) 2016-11-02 2018-05-11 Debiopharm International, S.A. Methods for improving anti-cd37 immunoconjugate therapy
KR101940806B1 (ko) * 2017-04-21 2019-01-21 (주)웅비식품 포장김 절단기
CN110412267B (zh) * 2018-04-28 2023-04-11 洛阳普泰生物技术有限公司 犬副流感病毒单克隆抗体及其应用
CN112384530B (zh) * 2018-07-10 2024-02-06 国家医疗保健研究所 戊型肝炎病毒orf2i蛋白的表位肽
US20210324049A1 (en) * 2018-07-10 2021-10-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity for the orf2i protein of hepatitis e virus and uses thereof for diagnostic purposes
CN109913424B (zh) * 2019-03-28 2020-10-27 浙江大学 一种包含戊型肝炎病毒复制子的人肝癌细胞系、应用及构建方法
GB201904328D0 (en) * 2019-03-28 2019-05-15 Immunocore Ltd Specific binding molecules
JPWO2023282243A1 (es) * 2021-07-06 2023-01-12
WO2023174976A1 (en) 2022-03-16 2023-09-21 Universität Zu Lübeck Broadly neutralizing antibodies against hepatitis e virus
CN114957411B (zh) * 2022-05-25 2023-08-18 徐州医科大学 一种正戊型肝病毒属基因c1型病毒orf2重组蛋白及其制备方法和应用
CN116298305B (zh) * 2023-01-03 2024-05-28 郑州大学 一种抗nt5c1a自身抗体检测方法及体外诊断试剂盒

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4470925A (en) 1982-05-05 1984-09-11 E. I. Du Pont De Nemours And Company Immunoglobulin half-molecules and process for producing hybrid antibodies
US4474493A (en) 1982-09-09 1984-10-02 Modular Systems, Inc. Dowel fastener and joints including same
US5686239A (en) 1988-06-17 1997-11-11 Genelabs Technologies, Inc. Hepatitis E virus peptides and methods
US5885768A (en) 1988-06-17 1999-03-23 The United States Of America As Represented By The Department Of Health And Human Services Hepatitis E virus peptide antigen and antibodies
US6291641B1 (en) * 1988-06-17 2001-09-18 Genelabs Technologies, Inc. Hepatitis E virus antigens and uses therefor
US5741490A (en) 1988-06-17 1998-04-21 Genelabs Technologies, Inc. Hepatitis E virus vaccine and method
US5219990A (en) * 1991-01-28 1993-06-15 Biogen, Inc. Papillomavirus e2 trans-activation repressors
JP2908107B2 (ja) 1992-03-19 1999-06-21 株式会社日立製作所 放射性廃棄物用固化材及び放射性廃棄物の処理方法
ES2336282T3 (es) * 1992-09-18 2010-04-09 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Proteinas recombinantes de una cepa paquistani de hepatitis e y su utilizacion en metodos de diagnostico y vacunas.
US5736315A (en) 1992-10-21 1998-04-07 National Institute Of Health Methods and compositions for detecting anti-hepatitis E virus activity
JP3919830B2 (ja) * 1992-11-28 2007-05-30 財団法人化学及血清療法研究所 抗ネコヘルペスウイルス−１組換え抗体および該抗体をコードする遺伝子断片
AU694139B2 (en) * 1993-09-24 1998-07-16 Macfarlane Burnet Centre For Medical Research Limited, The Immunoreactive antigens of hepatitis E virus
JP3504963B2 (ja) * 1993-10-22 2004-03-08 智靖 羅 抗ヒト高親和性ＩｇＥ受容体モノクローナル抗体に係るアミノ酸配列をコードするＤＮＡ断片
US5830636A (en) * 1993-12-22 1998-11-03 Abbott Laboratories HEV orf-2 monoclonal antibodies and methods for using same
CA2179609A1 (en) 1993-12-22 1995-06-29 Deborah A. Paul Monoclonal antibodies against hev orf-2 and methods for using same
EP0736088A1 (en) * 1993-12-22 1996-10-09 Abbott Laboratories Monoclonal antibodies to hepatitis e virus and methods for using same
US5830635A (en) * 1995-03-31 1998-11-03 Agnello; Vincent Method of detecting hepatitis C virus in tissues
ATE364631T1 (de) 1999-12-01 2007-07-15 Us Gov Health & Human Serv Hauptneutralisationsort des hepatitis e virus und verwendung dieses neutralisationsort in impfungverfahren und in verfahren zum screening nach neutralisationsantikörper
CA2405084C (en) * 2000-04-07 2011-06-14 Howard A. Fields Neutralizing immunogenic hev polypeptides
CN1345775A (zh) * 2000-09-30 2002-04-24 养生堂有限公司 用于预防、诊断及治疗戊型肝炎病毒的多肽,及它们作为诊断试剂和疫苗
WO2003040187A1 (fr) * 2001-11-08 2003-05-15 Yang Sheng Tang Company Limited Anticorps monoclonaux du virus de l'hepatite e ou fragments liants en provenant et utilisation correspondante
JP2010053113A (ja) 2008-08-26 2010-03-11 Sadanao Namiki 薬物輸送に利用できる自己会合型磁性脂質ナノ粒子、及びその製造方法
JP5264792B2 (ja) 2010-01-25 2013-08-14 三菱電機株式会社 プレート式熱交換器

Also Published As

Publication number Publication date
EP2322625B1 (en) 2016-01-06
WO2003040187A1 (fr) 2003-05-15
CN1610697A (zh) 2005-04-27
US20100003281A1 (en) 2010-01-07
US9428554B2 (en) 2016-08-30
US7786264B2 (en) 2010-08-31
BR122015016384B8 (pt) 2021-07-27
BR0214188A (pt) 2004-09-14
KR20050044384A (ko) 2005-05-12
BRPI0214188B1 (pt) 2016-08-02
US20060233822A1 (en) 2006-10-19
JP2010213693A (ja) 2010-09-30
CN100339395C (zh) 2007-09-26
EP2322625A1 (en) 2011-05-18
JP5341799B2 (ja) 2013-11-13
EP1452541A4 (en) 2005-07-20
EP2322625B8 (en) 2016-02-24
JP6016699B2 (ja) 2016-10-26
EP1452541B1 (en) 2012-06-20
BR122015016384B1 (pt) 2017-02-07
JP2013226136A (ja) 2013-11-07
JP2005524386A (ja) 2005-08-18
AU2002349727B2 (en) 2008-10-16
BRPI0214188B8 (pt) 2021-05-25
EP1452541B2 (en) 2015-06-17
KR101020256B1 (ko) 2011-03-08
EP1452541A1 (en) 2004-09-01

Similar Documents

Publication Publication Date Title
MXPA04004321A (es) Anticuerpo monoclonal contra virus de hepatitis e o su fragmento con actividad de enlace y uso del mismo.
RU2363707C2 (ru) Искусственные белки с пониженной иммуногенностью
WO2002000692A3 (en) Pd-l2 molecules: pd-1 ligands and uses therefor
WO2005056600A3 (en) Monoclonal antibodies that bind or neutralize dengue virus
DK0835315T3 (da) Vaccine til porcint reproduktivt og respiratorisk syndrom virus
DE69936977D1 (de) Durch polynukleinsäuren vom reproduktiven und respiratorischen syndromvirus des schweines kodierte proteine
NZ503763A (en) Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
MX348154B (es) Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
WO2003070760A3 (en) Anti-amyloid beta antibodies and their use
WO2001031019A3 (en) Neisserial antigenic peptides
JP2006526414A5 (es)
DK1278534T3 (da) Fremgangsmåder og sammensætninger til svækkelse af multiplikationen af HIV-1
Balmelli et al. FcγRII‐dependent sensitisation of natural interferon‐producing cells for viral infection and interferon‐α responses
WO2005016132A3 (en) Diagnostics for sars virus
DE69534600D1 (de) Nukleotid- und aminosäuresequenzen der gene des hüllproteins 1 und des kernproteins von hepatitis c virus
EP2298793A3 (en) Polypeptide fragments of hepatitis E virus, vaccine composition comprising said fragments and diagnostic kits
WO2001021807A8 (en) Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
CA2327353A1 (en) Structural proteins of fish pancreatic disease virus and uses thereof
EP0972054A4 (en) INCREASING IMMUNE RESPONSE USING TARGETED MOLECULES
HUP0302566A2 (hu) Készítmények és eljárások emlőrák gyógykezelésére és diagnosztizálására
ATE480620T1 (de) Neue pgc-1-isoformen und deren verwendungen
WO2001055353A3 (en) Recombinant attenuation of prrsv
WO2001049712A3 (en) Vaccine against isav (infectious salmon anaemia virus)
CA2491726A1 (en) Feline infectious peritonitis vaccine
WO2001046696A3 (en) Methods and compositions for detecting hepatitis e virus

Legal Events

Date Code Title Description
GB Transfer or rights
FG Grant or registration